Pfizer’s new COVID pill cuts hospitalisation or death by 89%, trial results indicate

Pfizer’s new experimental COVID-19 antiviral pill cuts the risk of hospitalisation or death by 89%, the company has announced.

The results appear to surpass those seen with Merck & Co Inc’s pill Molnupiravir, which was shown last month to halve the likelihood of dying or needing hospital treatment for COVID-19.

Full trial data is not yet available from either company.

Pfizer plans to submit the interim trial results to the US Food and Drug Administration as part of an emergency use application.

Mark Gibson

Graduates in Northwestern University, Evanston, Illinois 1990. Move to Los Angeles California in 2004. Specialized in Internet journalism.

Leave a Reply

Your email address will not be published. Required fields are marked *